Panel discussion
Takeda Pharma AG
| Country: | Switzerland |
| Website: | https://www.takeda.com/de-ch/ |
| Room: | Osaka/Samarkand |
| Date: | 03.05.2022 |
| Time: | 13:30 – 14:15 |
Panel title
The pathway of orphan drugs: From development to patient access in Switzerland
Panel summary
Orphan Drugs are important medicines for rare diseases – an area characterized by few patients per indication, but many different diseases. For 95% of the rare diseases there is no approved therapy available, indicating the high unmet medical need. The panel discusses several particularities of rare diseases from different perspectives
Speaker information
Moderation
Andreas Uttenweiler , Head Patient Value Access & Public Affairs, Takeda Pharma AG
Panelists
- Pierre Morneau, General Manager Switzerland, Takeda Pharma AG
- Markus Ziegler, Head Market and IPR, Interpharma
- Jasmin Barman, International Porphyria Patient Network
- Nicholas Benedict, CEO & Co-Founder, Vaderis Therapeutics AG
Company profile
Takeda is a leading biopharmaceutical company. Worldwide, more than 50,000 employees are committed to improving patients’ lives. Takeda Switzerland is based in Zurich, with the HQ for Europe and Canada. The focus of its 90 employees are approval and distribution of medicines for the Swiss market. The production site in Neuchâtel produces recombinant blood clotting factors for the global market. Takeda’s focusses on: Rare Diseases, Gastroenterology, NeuroScience and Oncology
